Board of Directors
News & Events
news & events
News and Events
more about CM-24
more about NT-219
Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
Purple Biotech to participate and Present at the Jefferies London Healthcare Conference
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay
Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
in Mar 13, 2023
Skip to content